Compare Incyte Corporation (INCY) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Otis Worldwide Corp — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while Otis Worldwide Corp trades at $73.45 (market cap $27.80B). The key difference: Incyte Corporation and Otis Worldwide Corp are close in size by market cap, and Otis Worldwide Corp pays a 2.41% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | OTIS | |
|---|---|---|
Market Cap | $24.54B | $27.80B |
Sector | Health | Industrials |
52-Week High | $129.93 | $93.62 |
52-Week Low | $81.61 | $69.34 |
Enterprise Value | $20.04B | $35.84B |
Dividend Yield | — | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Otis Worldwide (OTIS) trades at $73.82, up 1.3% for the day, with a neutral technical signal. Recent Q2 2026 earnings showed a beat on EPS but included guidance cuts, reflecting margin pressures from labor costs. The company maintains strong service segment growth, with modernization revenue up 24%, though new equipment demand remains weak. Cash flow trends show variability, with 2025 net cash flow negative $1.22 billion due to financing activities, while 2026 projects a positive $146 million.
The investment outlook is mixed; analyst consensus is a Buy with a $92.50 price target, implying significant upside, but risks include persistent margin compression and economic sensitivity. The stock's current valuation below historical averages presents a potential opportunity if service margins stabilize and growth accelerates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
